Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics - BRNS News | RalliesBarinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
B
BRNS• Proposed combination update
- Barinthus Biotherapeutics PLC said the scheme exchange ratio has been set at 0.111 for the Barinthus Bio and Clywedog merger.
- The scheme of arrangement is expected to become effective on Sept. 3, 2026.
- Barinthus Bio ADSs are expected to cease Nasdaq trading when the scheme becomes effective.
MATX
•
